260 related articles for article (PubMed ID: 21209944)
1. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor.
Ganapathy S; Chen Q; Singh KP; Shankar S; Srivastava RK
PLoS One; 2010 Dec; 5(12):e15627. PubMed ID: 21209944
[TBL] [Abstract][Full Text] [Related]
2. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis.
Shankar S; Ganapathy S; Chen Q; Srivastava RK
Mol Cancer; 2008 Jan; 7():16. PubMed ID: 18226269
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells.
Chen Q; Ganapathy S; Singh KP; Shankar S; Srivastava RK
PLoS One; 2010 Dec; 5(12):e15288. PubMed ID: 21179458
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Shankar S; Ganapathy S; Srivastava RK
Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
[TBL] [Abstract][Full Text] [Related]
5. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
Shankar S; Chen Q; Ganapathy S; Singh KP; Srivastava RK
Mol Cancer Ther; 2008 Aug; 7(8):2328-38. PubMed ID: 18723480
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
7. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo.
Shankar S; Chen X; Srivastava RK
Prostate; 2005 Feb; 62(2):165-86. PubMed ID: 15389801
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells.
Shankar S; Siddiqui I; Srivastava RK
Mol Cell Biochem; 2007 Oct; 304(1-2):273-85. PubMed ID: 17636462
[TBL] [Abstract][Full Text] [Related]
9. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
10. EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.
Shankar S; Marsh L; Srivastava RK
Mol Cell Biochem; 2013 Jan; 372(1-2):83-94. PubMed ID: 22971992
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
12. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
13. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer.
Modur V; Nagarajan R; Evers BM; Milbrandt J
J Biol Chem; 2002 Dec; 277(49):47928-37. PubMed ID: 12351634
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors.
Roy SK; Chen Q; Fu J; Shankar S; Srivastava RK
PLoS One; 2011; 6(9):e25166. PubMed ID: 21980390
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway.
Sheth S; Jajoo S; Kaur T; Mukherjea D; Sheehan K; Rybak LP; Ramkumar V
PLoS One; 2012; 7(12):e51655. PubMed ID: 23272133
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol as a novel agent for treatment of multiple myeloma with matrix metalloproteinase inhibitory activity.
Sun CY; Hu Y; Guo T; Wang HF; Zhang XP; He WJ; Tan H
Acta Pharmacol Sin; 2006 Nov; 27(11):1447-52. PubMed ID: 17049120
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
El-Zawahry A; McKillop J; Voelkel-Johnson C
BMC Cancer; 2005 Jan; 5():2. PubMed ID: 15638938
[TBL] [Abstract][Full Text] [Related]
19. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
20. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
